New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:37 EDTSQNM, CI, AETNew guidelines on Sequenom test to be considered by insurers, WP says
New prenatal tests for genetic defects that require only a sample of the mother’s blood, as opposed to an invasive procedure, have come under scrutiny from major insurance companies for their high cost and limited data on accuracy and impact on care, reported The Washington Post. A new opinion from the The American College of Obstetricians and Gynecologists will be considered by insurers including Cigna (CI) and Aetna (AET) but is not considered "a clear endorsement” of the tests offered by Sequenom (SQNM) and others, according to the report. Reference Link
News For SQNM;CI;AET From The Last 14 Days
Check below for free stories on SQNM;CI;AET the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 29, 2014
18:35 EDTSQNMOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTSQNMSequenom reports Q2 adjusted EPS (7c), consensus (11c)
Subscribe for More Information
16:32 EDTSQNMSequenom enters license agreement with Mayo Medical Laboratories
Subscribe for More Information
10:04 EDTAETAetna weakness a buying opportunity, says UBS
Subscribe for More Information
10:02 EDTAETAetna falls after results, levels to watch
Subscribe for More Information
06:16 EDTAETAetna raises 2014 Coventry accretion projection by 5c-10c to 55c-60c
Subscribe for More Information
06:15 EDTAETAetna raises FY14 EPS to $6.45-$6.60 from $6.35-$6.55, consensus $6.54
Subscribe for More Information
06:14 EDTAETAetna raises 2014-end medical membership to 23.4M members from 23M
Subscribe for More Information
06:13 EDTAETAetna expects to achieve targeted high single-digit pretax operating margin 2014
06:03 EDTAETAetna reports Q2 operating EPS $1.69, consensus $1.60
Subscribe for More Information
July 28, 2014
15:47 EDTAETNotable companies reporting before tomorrow's open
Subscribe for More Information
14:58 EDTAETEarnings Preview: Aetna shares up 16% since last earnings report
Subscribe for More Information
10:36 EDTAETAetna and Geisinger Health System reach five-year agreement
Subscribe for More Information
July 25, 2014
12:11 EDTAET, CIWellCare profit warning sinks managed care names
A number of managed care names are falling after one of the companies in the sector, WellCare (WCG), preannounced significantly weaker than expected results. UBS, however, recommends using the weakness in the sector as a buying opportunity. WHAT'S NEW: WellCare, which specializes in managing Medicaid and Medicare plans, preannounced a second quarter per share loss of 7c, excluding certain items. Analysts on average expected the company to report a per share profit of 90c. The company's revenue came in slightly above expectations. WellCare cut its full-year earnings per share guidance to $2.20-$2.50 from $4.40-$4.75. The company said recipients of a new Medicaid program in Florida utilized more medical services than expected since the company began administering the program in May. Additionally, the company took an impairment charge related to an acquisition and it had an unfavorable reserve development. ANALYST REACTION: The factors cited by WellCare for the cut in its guidance appear to be specific to that company, UBS analyst A.J. Rice wrote. Meanwhile, data from other companies that administer Medicaid plans indicate that the increased utilization costs in that state are also specific to WellCare, Rice contended. For example, Centene (CNC) reported Q2 results earlier this week and indicated that utilization trends for newly covered beneficiaries in Florida was largely in line with expectations, while UnitedHealth (UNH) said its Medicaid business had performed well last quarter, the analyst stated. Additionally, WellCare said that its higher than expected medical utilization costs had been caused primarily by drug costs that exceeded its forecast, Rice stated. Since drug costs tend to be known relatively quickly, United Health and Centene would have divulged any issues with drug costs in conjunction with their Q2 results, Rice said. The analyst recommended that investors buy Aetna (AET), Cigna (CI), United Health and WellPoint (WLP) on any weakness today. PRICE ACTION: In late morning trading, Aetna fell 1.5% to $83, Cigna lost 1% to $95.50, UnitedHealth lost 1% to $84.50, WellPoint slid 1.5% to $113.50 and Centene tumbled 7% to $74 while WellCare plunged 19% to $62.
10:52 EDTAET, CIWellCare issues largely company-specific, says UBS
UBS notes that aside from WellCare (WCG), which attributed its lowered guidance to the start-up of its Florida MMA program and other issues, that Centene (CNC), WellPoint (WLP), UnitedHealth (UNH) and Humana (HUM) are the leaders in Medicaid in the state. However, the firm believes a majority of WellCare's issues appear company specific and UBS views any weakness in UnitedHealth, WellPoint, Aetna (AET), or Cigna (CI) as opportunity to buy those four stocks, on all of which it has Buy ratings.
July 24, 2014
06:50 EDTCI, AETConsumers received $9B in refunds from health insurers, The Hill says
Subscribe for More Information
July 22, 2014
13:46 EDTCI, AETCourt upholds Obamacare subsidies, NY Times says
Subscribe for More Information
10:43 EDTCI, AETAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRS’s regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use